BRTX Stock - BioRestorative Therapies, Inc.
Unlock GoAI Insights for BRTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $401,000 | $145,800 | $119,800 | $46,000 | $77,000 |
| Gross Profit | $372,928 | $145,800 | $119,800 | $46,000 | $77,000 |
| Gross Margin | 93.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-11,555,194 | $-15,220,774 | $-18,974,025 | $-26,307,873 | $-2,752,076 |
| Net Income | $-8,979,381 | $-10,417,704 | $-13,222,296 | $-44,303,295 | $-11,272,687 |
| Net Margin | -2239.2% | -7145.2% | -11037.0% | -96311.5% | -14639.9% |
| EPS | $-1.16 | $-2.47 | $-3.65 | $-37.30 | $-28.56 |
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.
Visit WebsiteEarnings History & Surprises
BRTXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.35 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.38 | $-0.38 | 0.0% | = MET |
Q3 2025 | Aug 12, 2025 | $-0.41 | $-0.30 | +26.8% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.32 | $-0.56 | -75.0% | ✗ MISS |
Q1 2025 | Mar 27, 2025 | $-0.27 | $-0.20 | +25.9% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.35 | $-0.13 | +62.9% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.56 | $-0.50 | +10.7% | ✓ BEAT |
Q2 2024 | Jun 11, 2024 | $-0.51 | $-0.53 | -3.9% | ✗ MISS |
Q1 2024 | Mar 29, 2024 | $-0.65 | $-0.57 | +12.3% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.68 | $-0.64 | +5.9% | ✓ BEAT |
Q3 2023 | Aug 11, 2023 | $-1.56 | $-0.77 | +50.6% | ✓ BEAT |
Q2 2023 | May 12, 2023 | $-1.26 | $-1.53 | -21.4% | ✗ MISS |
Q1 2023 | Mar 24, 2023 | $-1.43 | $-1.18 | +17.5% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-0.49 | $-1.28 | -161.2% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-0.55 | $-1.28 | -132.7% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-0.63 | $1.37 | +317.5% | ✓ BEAT |
Q1 2022 | Mar 30, 2022 | $-0.54 | $-6.90 | -1177.8% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | — | $-4.99 | — | — |
Q3 2021 | Aug 16, 2021 | — | $-4.85 | — | — |
Q2 2021 | May 17, 2021 | — | $-19.72 | — | — |
Latest News
BioRestorative Granted FDA Type B Meeting To Discuss Accelerated BLA Approval Pathway fFr BRTX-100 In Chronic Lumbar Disc Disease
📈 PositiveBioRestorative Therapies Q3 EPS $(0.33) Beats $(0.36) Estimate, Sales $11.800K Miss $460.000K Estimate
📉 NegativeBioRestorative Secures Notice of Allowance For Japanese Patent For ThermoStem Platform
📈 PositiveBRTX stock has given up its prior loss. BioRestorative Therapies shares were trading lower after the company announced the pricing of its $1.085 million offering of 678,125 shares at $1.60 per share.
➖ NeutralBioRestorative Therapies shares are trading lower after the company announced the pricing of its $1.085 million offering of 678,125 shares at $1.60 per share.
📉 NegativeBioRestorative Therapies Reveals $1.085M Registered Direct Offering Priced Above Market
📈 PositiveBioRestorative Therapies announces share repurchase program; shares gain over 8%
📈 PositiveFrequently Asked Questions about BRTX
What is BRTX's current stock price?
What is the analyst price target for BRTX?
What sector is BioRestorative Therapies, Inc. in?
What is BRTX's market cap?
Does BRTX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BRTX for comparison